Company research
Evoke Pharma Inc
CIK 1403708Updated Sep 24, 2026
SecurityEVOK · OTC · equity
EVOK price & chart
Loading TradingView…
OTC:EVOK on TradingView ↗In the news
No coverage from other publishers is available.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 17,519,007Source | 8,979,697Source | 11,851,488Source | 10,573,162Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 13,596,600Source | 7,006,431Source | 9,843,699Source | 9,144,710Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 1,023,813Source | — | — |
| Inventory, NetUSD | 445,081Source | 513,712Source | 289,378Source | 185,534Source |
| Assets, CurrentUSD | 17,237,897Source | 8,926,855Source | 11,722,414Source | 10,560,734Source |
| Operating Lease, Right-of-Use AssetUSD | 154,184Source | 52,842Source | 129,074Source | 12,428Source |
| Other Assets, NoncurrentUSD | 6,312Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 10,480,997Source | 8,441,323Source | 7,766,839Source | 7,018,068Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 149Source | 334Source | 334Source | 3,266Source |
| Retained Earnings (Accumulated Deficit)USD | -128,791,632Source | -119,758,130Source | -115,647,143Source | -107,423,013Source |
| Stockholders' Equity Attributable to ParentUSD | 7,038,010Source | 538,374Source | 4,084,649Source | 3,555,094Source |
| Additional Paid in Capital, Common StockUSD | 135,829,493Source | 120,296,170Source | 119,731,458Source | 110,974,841Source |
| Liabilities and EquityUSD | 17,519,007Source | 8,979,697Source | 11,851,488Source | 10,573,162Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 10,380,039Source | 8,441,323Source | 1,654,544Source | 1,405,773Source |
| Operating Lease, Liability, CurrentUSD | 59,533Source | 52,842Source | 129,074Source | 12,428Source |
| Operating Lease, Liability, NoncurrentUSD | 100,958Source | — | — | — |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 773,121Source | 1,128,109Source | 1,458,709Source | 1,878,954Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,747,302Source | 48,239Source | 329,639Source | 271,882Source |
| Increase (Decrease) in InventoriesUSD | -32,839Source | 192,462Source | 103,843Source | -20,946Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,458,742Source | -4,984,977Source | -6,595,987Source | -12,352,944Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 14,315,916Source | -119,296Source | 7,294,976Source | 13,428,715Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,857,174Source | -5,104,273Source | 698,989Source | 1,075,771Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 13,596,600Source | 4,739,426Source | 9,843,699Source | — |
| Additional Financial Items | ||||
| Inventory Write-downUSD | — | — | — | 30,000Source |
| Investment Income, InterestUSD | 353,313Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -5,352,194Source | -7,792,295Source | -8,224,130Source | -8,537,952Source |
| Nonoperating Income (Expense)USD | — | -361,404Source | -437,993Source | -386,305Source |
| Operating ExpensesUSD | 15,453,552Source | 12,611,521Source | 10,294,782Source | 9,769,723Source |
| Operating Lease, ExpenseUSD | — | — | — | 136,000Source |
| Other Nonoperating Income (Expense)USD | -148,057Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | 13,070,154Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 45,454Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 10,249,415Source | 5,180,630Source | 2,508,645Source | 1,618,076Source |
| Selling, General and Administrative ExpenseUSD | 15,080,699Source | 12,227,735Source | 9,623,599Source | 8,851,129Source |
| Operating Income (Loss)USD | -5,204,137Source | -7,430,891Source | -7,786,137Source | -8,151,647Source |
| Other Nonoperating Income (Expense)USD | -148,057Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -5,352,194Source | -7,792,295Source | -8,224,130Source | -8,537,952Source |
| Earnings Per Share, BasicUSD per share | -2.81Source | -2.33Source | -2.62Source | — |
| Earnings Per Share, DilutedUSD per share | -2.81Source | -2.33Source | -2.62Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,905,072Source | 3,343,070Source | 3,143,626Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,905,072Source | 3,343,070Source | 3,143,626Source | — |
| Additional Financial Items | ||||
| Interest ExpenseUSD | 501,370Source | 500,000Source | 500,000Source | 500,050Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | 138,596Source | 62,007Source | 8,615Source |
| Investment Income, InterestUSD | 353,313Source | — | — | — |
| Nonoperating Income (Expense)USD | — | -361,404Source | -437,993Source | -386,305Source |
| Operating ExpensesUSD | 15,453,552Source | 12,611,521Source | 10,294,782Source | 9,769,723Source |
| Operating Lease, ExpenseUSD | — | — | — | 136,000Source |